Explore Raloxifene dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Raloxifene is an estrogen-modulating drug (a SERM) approved as Evista for osteoporosis, sourced in research for bone and estrogen-balance studies. It ships as tablets or a research-grade powder.
Raloxifene binds estrogen receptors as a competitive antagonist in breast tissue and as a partial agonist in bone — the same SERM-class tissue selectivity that defines tamoxifen, but with a different conformational fingerprint at the receptor that results in absent (rather than partial-agonist) activity at the endometrium. The bone-protective effect derives from estrogen-like inhibition of osteoclast-mediated bone resorption; the breast risk-reduction effect derives from estrogen-receptor antagonism in mammary tissue. Cardiovascular and lipid effects are mixed: raloxifene improves LDL cholesterol but increases the risk of fatal stroke and venous thromboembolism, the dominant safety considerations in chronic use.[3]
The MORE trial (Ettinger et al., JAMA 1999) established that raloxifene 60mg daily reduced vertebral fracture incidence in postmenopausal osteoporosis by 30–50% over 3 years.[4] The MORE breast-cancer secondary analysis (Cummings et al., JAMA 1999) reported a 76% reduction in invasive breast-cancer incidence over the same period.[5] STAR (Vogel et al., JAMA 2006) directly compared raloxifene with tamoxifen for breast-cancer risk reduction in postmenopausal women, with raloxifene producing similar invasive-cancer reduction and a better thromboembolic and uterine-safety profile.[6] RUTH (Barrett-Connor et al., NEJM 2006) tested raloxifene for cardiovascular outcomes in postmenopausal women at high cardiovascular risk and showed no cardiovascular benefit but increased fatal-stroke and venous-thromboembolism risk.[7]
FDA-approved as Evista for prevention and treatment of postmenopausal osteoporosis (1997) and for reduction of invasive breast cancer risk in postmenopausal women at high risk or with osteoporosis (2007). Not approved for premenopausal use. Research-grade material elsewhere.
Raloxifene has a reported half-life of ~28 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. With a ~28-hour half-life dosed once daily, raloxifene builds up over several days to a steady level. Missing a single day has only a small effect on overall exposure. Pharmacokinetic source: FDA label (Evista). It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough Raloxifene calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.